Advertisement
UK markets closed
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • FTSE 250

    20,164.54
    +112.24 (+0.56%)
     
  • AIM

    771.53
    +3.42 (+0.45%)
     
  • GBP/EUR

    1.1657
    -0.0026 (-0.22%)
     
  • GBP/USD

    1.2551
    +0.0017 (+0.14%)
     
  • Bitcoin GBP

    50,794.68
    +1.69 (+0.00%)
     
  • CMC Crypto 200

    1,312.63
    +35.65 (+2.79%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +449.98 (+1.18%)
     
  • CRUDE OIL

    77.99
    -0.12 (-0.15%)
     
  • GOLD FUTURES

    2,310.10
    +1.50 (+0.06%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • HANG SENG

    18,475.92
    +268.82 (+1.48%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS, January 31, 2024--(BUSINESS WIRE)--Regulatory News:

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)

Under the liquidity contract entered into between Valerio Therapeutics and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2023:

- 368,174 shares
- € 144,918.05

- Number of executions on buy side on semester: 324
- Number of executions on sell side on semester: 244
- Traded volume on buy side on semester: 304,205 shares for € 69,976.87
- Traded volume on sell side on semester: 223,191 shares for € 56,117.81

As a reminder :

  • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account:

ADVERTISEMENT

- 287,160 shares
- € 156,554.06

- Number of executions on buy side on semester: 509
- Number of executions on sell side on semester: 492
- Traded volume on buy side on semester: 634,648 shares for € 258,705.74
- Traded volume on sell side on semester: 923,185 shares for € 402,719.91

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131554337/en/

Contacts

Valerio Therapeutics S.A.